Yarrow Bioscience grants Ryder 113,137-share option

One quarter of the option vests on July 28, 2027; the balance vests monthly over three years, subject to continued service.

Available on EDGAR 10/30/2026 - 04:02 PM EDT Accepted by SEC EDGAR 10/30/2026 - 04:02 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Yarrow Bioscience, Inc. (YARW) Chief Medical Officer Steven Ryder was granted, on October 29, 2026, an option to purchase 113,137 common shares at an exercise price of $20 per share. One quarter vests on July 28, 2027, and the remaining three quarters vest in equal monthly installments over the following three years, subject to continued service on each vesting date. The option expires October 29, 2036.

Insider Trade Summary

Grant/Award: 113,137 shares

Grant/Award 1 txn

Insider Ryder Steven

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	113,137	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 113,137 contracts (Direct)

Footnotes (1)

1. F1. This option represents a right to purchase 113,137 shares of the Issuer's common stock, one quarter of which will vest on July 28, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

Key Figures

Option shares: 113,137 shares Exercise price: $20 per share Initial vesting tranche: One quarter +2 more

5 metrics

Option shares 113,137 shares Right to purchase common shares; granted October 29, 2026.

Exercise price $20 per share Option granted October 29, 2026.

Initial vesting tranche One quarter Vests July 28, 2027.

Remaining vesting period Following three years Remaining three quarters vest in equal monthly installments.

Option expiration October 29, 2036 Expiration date of the option.

Key Terms

right to purchase, vest, equal monthly installments

3 terms

right to purchase technical

"represents a right to purchase 113,137 shares"

vest technical

"one quarter of which will vest on July 28, 2027"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

equal monthly installments technical

"vesting in equal monthly installments over the following three years"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many YARW shares does Steven Ryder's new option cover?

Steven Ryder's option covers the right to purchase 113,137 common shares. It was granted October 29, 2026, with an exercise price of $20 per share.

What is the vesting schedule for Steven Ryder's YARW option?

One quarter vests on July 28, 2027. The remaining three quarters vest in equal monthly installments over the following three years, subject to Steven Ryder's continued service on each vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ryder Steven

(Last) (First) (Middle)

C/O YARROW BIOSCIENCE, INC.

470 JAMES STREET, SUITE 007

(Street)

NEW HAVEN CONNECTICUT 06513

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Yarrow Bioscience, Inc. [ YARW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$20	10/29/2026		A		113,137		(1)	10/29/2036	Common Stock	113,137	$0	113,137	D

Explanation of Responses:

1. This option represents a right to purchase 113,137 shares of the Issuer's common stock, one quarter of which will vest on July 28, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

	/s/ Tyler Zeronda, as attorney-in-fact for Steven Ryder	10/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)